- Advertisement -
TORONTO–(BUSINESS WIRE)–Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery…
Click here to view the original article.
